ECAP剂量在真实世界人群中通过EVOKE疗法应用的临床效用:ECAP研究
ECAP研究是一项前瞻性、多中心、单臂、实用性研究,在美国22个中心纳入慢性难治性躯干和/或肢体疼痛的脊髓刺激候选者,评估EVOKE闭环脊髓刺激系统在常规临床实践中的有效性。结果显示所有领域均获得>1个MCID改善,7个领域中有6个获得≥2个MCID改善;试验结束时观察到的改善在植入后访视时维持或进一步改善,整体MCID改善具有统计学显著性(MD 0.2,95%CI 0.1至0.4,p=0.004),整体MCID应答者比例显著更高(p=0.047)。亚组分析显示不同诊断亚组结果相似。
要点
- EVOKE闭环脊髓刺激在真实世界慢性疼痛人群中产生具有临床意义的改善。
- 所有PROMIS-29领域改善>1个MCID,6/7领域改善≥2个MCID。
- 试验期改善在植入后维持或提升,整体MCID应答者比例显著增加(p=0.047)。
核心结论
- EVOKE疗法在真实世界慢性疼痛人群中与具有临床意义的改善相关,且在不同亚组和疾病病理中效果相似。
- 试验结束时观察到的效果在植入后访视时得以重现。
研究设计与样本
- ECAP研究为前瞻性、多中心、单臂、实用性研究,在美国22个研究站点纳入慢性难治性躯干和/或肢体疼痛的脊髓刺激候选者。
- 收集PROMIS-29问卷和客观神经生理学指标,使用最小临床重要差异(MCID)表征基线功能障碍和对EVOKE疗法的应答。
- 预设基于诊断的亚组分析。
主要发现
- EVOKE疗法观察到剂量比为1.3,神经剂量准确性为2.8 μV。
- 所有领域均观察到>1个MCID的改善,7个领域中有6个观察到≥2个MCID的改善。
- 试验结束时观察到的改善在植入后访视时维持或改善,整体MCID改善具有统计学显著性(MD 0.2,95%CI 0.1至0.4,p=0.004),整体MCID应答者比例显著更高(p=0.047)。
- 按诊断进行的亚组分析显示相似结果。
临床怎么用
- 在常规临床实践中,EVOKE闭环脊髓刺激可用于慢性难治性躯干和/或肢体疼痛患者,并预期获得具有临床意义的改善。
- 治疗应答可在试验期评估,并在植入后维持或进一步提升。
局限性
- 研究为单臂设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. METHODS: The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. RESULTS: EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. CONCLUSIONS: EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
引用
- Pope JE, Smith GL, Goree JA, et al. Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study. Reg Anesth Pain Med. 2025. PMID: 41330601. doi:10.1136/rapm-2025-107051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。